Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Evotec Buys Kinaxo, Works With ChemBridge
by Michael McCoy
February 21, 2011
| A version of this story appeared in
Volume 89, Issue 8
The German contract research organization Evotec has acquired Kinaxo, a Munich-based company that offers technologies for response prediction and safety assessment in drug development. Evotec will pay about $16 million and could make $5 million in additional payments depending on Kinaxo’s performance. Separately, Evotec will work with ChemBridge to expand its screening library. Evotec will enhance its library of 250,000 druglike compounds with an initial 110,000 compounds from ChemBridge.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter